These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX. NERLYNX ® (neratinib) tablets, for oral use Initial U.S. Approval: 2017
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Files NDS for Nerlynx in Canada | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
Puma Biotechnology Inc shares gain on NERLYNX approval news
Puma biotech and Specialised Therapeutics signs agreement to commercialize NERLYNX®
Puma Study Probes Nerlynx Side Effects | Los Angeles Business Journal
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib) | PharmaShots
puma biotechnology earnings Off 66% - canerofset.com
NERLYNX Dosage & Rx Info | Uses, Side Effects
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates
Puma Biotechnology and Pierre Fabre's Amendment of NERLYNX License Agreement – Global Legal Chronicle
Puma Biotechnology
Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | News Hub Asia
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology
Home │ NERLYNX® (neratinib) tablets
Puma Biotechnology
Nerlynx Labeling Updated to Include Data on Antidiarrheal Prophylaxis - MPR
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
